<DOC>
	<DOCNO>NCT02781844</DOCNO>
	<brief_summary>This study conduct characterize effect twice daily administration rhPTH ( 1-84 ) way body handle rhPTH ( 1-84 ) well action , safety tolerability course 24-36 hour compare current daily dose regimen market rhPTH ( 1-84 ) ( market United States Natpara® ) .</brief_summary>
	<brief_title>Study Assess Blood Concentrations Actions Recombinant Human Parathyroid Hormone ( rhPTH 1-84 ) When Given Once Twice Daily Subjects With Hypoparathyroidism</brief_title>
	<detailed_description />
	<mesh_term>Hypoparathyroidism</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Key 1 . History hypoparathyroidism ≥ 12 month . 2 . Requirement supplemental oral calcium treatment ≥ 1000 mg per day . 3 . Requirement active vitamin D therapy dose ≥ 0.25 mcg per day . ( i.e. , ≥ 0.25 mcg calcitriol equivalent per day ) . 4 . Serum calcium level ≥7.0 ≤9.5 mg/dL ( 1.752.375 mmol/L ) base local clinical chemistry lab result Screening ( central lab ) Treatment Period 1 , Day 2 ( central and/or local lab ) . 5 . Urinary calcium excretion ≥250 mg ( 6.25mmol ) /24h usual calcium active vitamin D supplementation , base historical ( ie within 12 month ) data provide subject 's physician . 6 . Urinary calcium excretion ≥200 mg ( 5mmol ) /24h , base 24hour collection prior checkin CRC Treatment Period 1 , Day 2 . 7 . Serum magnesium level within laboratory normal range screen examination , outside normal range , consider clincially significant Investigator . 8 . Serum thyroid function test within normal laboratory limit screen , outside normal range , consider clinically significant Investigator . 9 . Serum 25 ( OH ) D level lower limit normal 1.5 fold laboratory upper limit normal first screen visit . 10 . Serum creatinine &lt; 1.5 mg/dL ( &lt; 133 micromol/L ) AND creatinine clearance &gt; 60 mL/ minute ( &gt; 1.002mL/s ) . Key 1 . Participation investigational drug study within last 3 month 2 . Use follow prior study drug administration : ( 1 ) 30 day : loop diuretic , lithium , antacid , systemic corticosteroid ; ( 2 ) 3 month : calcitonin , cinacalcet hydrochloride , rhPTH ( 184 ) Nterminal PTH PTHrelated peptide fragment analog ; ( 3 ) female : change hormone replacement therapy within 3 month ; ( 4 ) 6 month : fluoride tablet , oral bisphosphonates , methotrexate growth hormone , digoxin ; raloxifene similar selective estrogen receptor modulators ; ( 5 ) 12 month : intravenous bisphosphonates , drug alcohol abuse 3 . History clinically significant disorder involve cardiovascular , respiratory , renal , gastrointestinal , immunologic , hematologic , endocrine ( exception condition study ) , neurologic system ( ) psychiatric disease determine Investigator . 4 . Known history hypoparathyroidism result activate mutation calcium sense receptor ( CaSR ) gene impaired responsiveness PTH ( pseudohypoparathyroidism ) . 5 . Any disease might affect calcium metabolism calciumphosphate homeostasis hypoparathyroidism 6 . Subjects increase baseline risk osteosarcoma . 7 . Subjects know history hypocalcemia initiation treatment follow abrupt withdrawal treatment PTH , PTH analogues fragment PTH . 8 . Subjects dependent regular paretneral calcium infusion maintain calcium homeostasis within 3 month prior enrollment . 9 . Any medical condition prior therapy , opinion investigator , would make subject unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>